Entera Bio
ENTX
26 hedge funds and large institutions have $8.68M invested in Entera Bio in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
18% more funds holding
Funds holding: 22 → 26 (+4)
3.21% less ownership
Funds ownership: 20.37% → 17.17% (-3.2%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
52% less capital invested
Capital invested by funds: $18.1M → $8.68M (-$9.45M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$513K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$288K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$185K |
| 4 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
+$98.5K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$32.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.66M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$760K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$606K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$126K |
| 5 |
Jane Street
New York
|
-$57.7K |
ENTX Hedge Fund Activity: Q1 2026 in Review
26 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q1 2026, worth a combined $8.68M — down 52% from $18.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ENTX positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $513K. The largest seller was Point72 Asset Management, cutting an estimated $1.66M.
- 26 institutional investors held Entera Bio (ENTX) as of Q1 2026, up from 22 in Q4 2025.
- Funds reported $8.68M of Entera Bio stock for Q1 2026, down 52% quarter-over-quarter.
- 8 funds opened new Entera Bio positions in Q1 2026 and 4 closed out, a net change of +4 holders.
- The largest Entera Bio buyer in Q1 2026 was Renaissance Technologies, an estimated $513K added.
- The largest Entera Bio seller in Q1 2026 was Point72 Asset Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q1 2026.